Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zomedica Corp. Common Shares (NY: ZOM )

0.1200 UNCHANGED
Official Closing Price Updated: 5:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,720,621
Open 0.1206
Bid (Size) 0.1202 (10)
Ask (Size) 0.1205 (203)
Prev. Close 0.1200
Today's Range 0.1195 - 0.1210
52wk Range 0.1170 - 0.2285
Shares Outstanding 979,949,668
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Zomedica Unveils New Canine Tests Offering Faster Diagnostics for Heart and Breeding Health
Zomedica Corp (AMEX: ZOM) launches 2 new canine assays for its TRUFORMA platform. NT-proBNP test detects heart failure, progesterone test helps with breeding timing. 
Via Benzinga
Zomedica Launches Two New Quantitative Assays on the TRUFORMA(R) Platform: Canine NT-proBNP and Progesterone
Via ACCESSWIRE

Performance

YTD
-35.34%
-35.34%
1 Month
-7.55%
-7.55%
3 Month
-7.83%
-7.83%
6 Month
-16.96%
-16.96%
1 Year
-45.92%
-45.92%

More News

Read More
Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer
Via ACCESSWIRE
Zomedica Corp (NYSE: ZOM) Featured in Coverage of NobleCon20
Via Investor Brand Network
Zomedica to Present at the NobleCon20 Twentieth Annual Emerging Growth Equity Conference December 4, 2024
Via ACCESSWIRE
Zomedica Launches Quantitative Insulin Assay for Equine Plasma on the TRUFORMA(R) Platform
Via ACCESSWIRE
Zomedica Launches Ear Cytology Quick Scan Protocol for TRUVIEW(TM) Digital Microscope & Telepathology Platform
Via ACCESSWIRE
Zomedica Announces Sponsorship of Educational Presentations at the Fetch Coastal Conference
Via ACCESSWIRE
Larry Heaton, CEO of Zomedica Corp. (NYSE: ZOM), to Present at NobleCon20
Via Investor Brand Network
Noble Capital Markets Initiates Equity Research Coverage on Zomedica
Via ACCESSWIRE
Zomedica to Present at the Sidoti Micro Cap Conference November 14, 2024
Via ACCESSWIRE
Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth
Via ACCESSWIRE
Zomedica to Report Third Quarter 2024 Financial Results and Provide Business Update on November 7th at 4:30 p.m. ET
Via ACCESSWIRE
Zomedica Announces Expansion of Exclusive Equine Distribution Agreement with Grovet in Europe
Via ACCESSWIRE
Zomedica Completes Renovation & Upgrade of Manufacturing, Distribution, and R&D Center in Plymouth, Minnesota
Via ACCESSWIRE
Zomedica Secures CE Mark for TRUVIEWTM Digital Microscope & Telepathology System, Expanding Global Market Opportunities
Via ACCESSWIRE
Zomedica Strengthens European Foothold With Grovet Partnership, Expanding PulseVet And TRUFORMA Reach
Via Benzinga
Zomedica's Assisi Loop(R) Product Line Designated as Fear Free(TM) Preferred Product
Via ACCESSWIRE
Zomedica Introduces Enhanced Audio Features for the VETGuardian(R) Zero-touch Vital Signs Remote Monitoring System
Via ACCESSWIRE
More Than $9M Bet On Nerdy? Check Out These 3 Penny Stocks Executives Are Aggressively Buying
Via Benzinga
Zomedica Announces Key Educational Presentations at Fetch dvm360 Veterinary Conference
Via ACCESSWIRE
ZOM Stock Earnings: Zomedica Misses Revenue for Q2 2024
Via InvestorPlace
Zomedica Announces Second Quarter 2024 Financial Results: Revenue of $6.1 Million; 71% Gross Margin, and $83.0 Million in Liquidity to Support Growth
Via ACCESSWIRE
Zomedica Continues Global Expansion Through Strategic Partnership with SIRE Veterinario, S.A for Sales Expansion in Central America
Via ACCESSWIRE
Zomedica Taps Into Costa Rica With Strategic Partnership With SIRE Veterinario
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.